1.1 DIASTOLIC LEFT VENTRICULAR FUNCTION IN RELATION TO CIRCULATING METABOLIC BIOMARKERS IN A GENERAL POPULATION
Zhen Yu Zhang*, Vannina Marrachelli, Lutgarde Thijs and 10 more
Artery Research · 2015
doi:10.1016/j.artres.2015.10.002 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Background: The metabolic signature associated with subclinical diastolic left ventricular (LV) dysfunction in the general population is unknown. Objectives: This population study aimed at identifying a specific profile of circulating me-tabolites associated with asymptomatic diastolic LV dysfunction. Methods: In 711 randomly recruited Flemish (50.8% women; mean age, 50.8 years), we assessed echocardiographic indexes of diastolic LV function in relation to 44 circulating metabolites determined by nuclear magnetic resonance spectroscopy. Statistical methods included multivariable-adjusted regression analyses and partial least square discriminant analysis (PLS DA). Results: In multivariable analyses with Bonferroni correction, a′ was inversely and e′/a′ was positively correlated (p ≤ 0.048) with circulating tyrosine, HDL apolipoproteins, glucose + glutamine, and an unidentified molecule, while a′ was also inversely associated with glucose + 2 aminobutyrate and glucose + 2 phosphoglycerate (p ≤ 0.031). PLS-DA identified three latent factors accounting for 54.4% of the variance. The metabolites associated with better diastolic LV function included, amongst others, glucose + glutamine (variable importance in projection score, 1.201), glucose + 2 aminobutyrate (1.185), and glucose + 2 phosphoglycerate (1.172). The three latent factors, compared with N-terminal prohormone brain natriuretic peptide, increased (p < 0.0001) the area under the curve from 0.64 to 0.73. Conclusions: In the general population, diastolic LV function is associated with a profile of circulating metabolites indicative of energy substrate utilization and protection against oxidative stress. These metabolic markers might lead to the discovery of new targets for prevention and treatment of diastolic LV dysfunction at a subclinical and still reversible stage.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.